Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Plasma Cell, Multiple Myeloma Cell Line
DISEASE(S): Multiple Myeloma
SUBMITTER: Keiji Kurata
LAB HEAD: Kenneth Carl Anderson
PROVIDER: PXD029453 | Pride | 2023-03-11
REPOSITORIES: pride
Items per page: 5 1 - 5 of 37 |
Kurata Keiji K James-Bott Anna A Tye Mark A MA Yamamoto Leona L Samur Mehmet K MK Tai Yu-Tzu YT Dunford James J Johansson Catrine C Senbabaoglu Filiz F Philpott Martin M Palmer Charlotte C Ramasamy Karthik K Gooding Sarah S Smilova Mihaela M Gaeta Giorgia G Guo Manman M Christianson John C JC Payne N Connor NC Singh Kritika K Karagoz Kubra K Stokes Matthew E ME Ortiz Maria M Hagner Patrick P Thakurta Anjan A Cribbs Adam A Mazitschek Ralph R Hideshima Teru T Anderson Kenneth C KC Oppermann Udo U
Blood cancer journal 20230112 1
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic data suggest that GluProRS promotes disease progression and is associated with poor prognosis, while downregulation in MM cells triggers apoptosis. We developed NCP26, a novel ATP-competitive ProRS inhibitor that ...[more]